Assembly Biosciences, INC 10-Q quarterly reports

Assembly Biosciences reports Q1 2026 financial results, highlighting progress in its viral disease pipeline and ongoing collaboration with Gilead Sciences.

Assembly Biosciences reported increased collaboration revenue and positive clinical trial data for its HSV programs, extending its cash runway into late 2027.

Assembly Biosciences reported continued losses and substantial doubt about its ability to continue as a going concern, despite advancing multiple clinical-stage antiviral programs and increasing collaboration revenue.

Assembly Biosciences reports a net loss of $8.8 million for Q1 2025, alongside progress in its clinical programs and collaboration with Gilead Sciences.

Assembly Biosciences reported its third quarter 2024 financial results, highlighting progress in its clinical programs and ongoing collaboration with Gilead Sciences.

Assembly Biosciences reported its second quarter 2024 financial results, highlighting progress in its clinical programs and ongoing collaboration with Gilead Sciences.

Assembly Biosciences reported a net loss of $9.1 million for the first quarter of 2024, while advancing its clinical programs and collaboration with Gilead.